Tumor cell clearance reimagined.
Our mission is to discover, translate, and deliver pioneering curative cell therapies that incorporate multiple forms of tumor clearance into single T cells.
CERs explained
Our technology aims to integrate anti-tumor capabilities of both the innate and adaptive immune systems into a single T cell.
› Exploiting a Natural Immune Process
The CER platform
We are advancing a CER T-cell platform that potentially offers novel approaches for the treatment of both hematologic malignancies and solid tumors.
› Therapeutic Potential of Our Platform
Join the quest
Our culture is mission-and innovation-driven towards bringing improved treatment options to patients. We are looking for talented and motivated individuals to join us in our quest.
› Careers at CERo
A differentiated mechanism of action for solid tumors
Check out pre-clinical data on CER T cell activity in NSCLC presented at the Society of Immunotherapy of Cancer (SITC) annual meeting.
› Read articleNews and events
Jun 05, 2023
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell TherapeuticsMay 15, 2023
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentationMay 02, 2022
CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard of Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models